LRRK2 Inhibitors

Mutations in the LRRK2 gene are risk-factors for developing Parkinson’s disease. Increased kinase activity of certain LRRK2 mutants is thought to underlie dopaminergic neuron damage. Thus, LRRK2 inhibitors offer the potential to target an underlying cause of the disease. Here is the latest research.

September 22, 2020

Discovery of a Series of Ester-substituted NLRP3 Inflammasome Inhibitors

Bioorganic & Medicinal Chemistry Letters
David HarrisonAlan P Watt
September 25, 2020

Phosphorylation of Rab GTPases in the regulation of membrane trafficking

Traffic
Dieter Waschbüsch, Amir R Khan
September 16, 2020

Somatic mutations in LRRK2 identify a subset of invasive mammary carcinomas associated with high mutation burden

The American Journal of Pathology
Edgardo R Parrilla CastellarLaurie H Sanders
September 15, 2020
Open Access

Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson's disease

Journal of Enzyme Inhibition and Medicinal Chemistry
Serena VittorioLaura De Luca
September 26, 2020
Open Access

TM4SF4 and LRRK2 are Potential Therapeutic Targets in Lung and Breast Cancers through Outlier Analysis

Cancer Research and Treatment : Official Journal of Korean Cancer Association
Kyungsoo JungYoon-La Choi
September 24, 2020
Preprint

LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease

MedRxiv : the Preprint Server for Health Sciences
Y. L. SoseroKonstantin Senkevich
September 24, 2020
Open Access

GDNF/RET Signaling Pathway Activation Eliminates Lewy Body Pathology in Midbrain Dopamine Neurons

Movement Disorders : Official Journal of the Movement Disorder Society
Piotr ChmielarzAndrii Domanskyi
September 18, 2020
Open Access

Association of rare variants in neurodegenerative genes with familial Alzheimer's disease

Annals of Clinical and Translational Neurology
Weiwei ZhangLu Shen
September 16, 2020
Open Access

Changes in the cellular fatty acid profile drive the proteasomal degradation of α-synuclein and enhance neuronal survival

FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
Mary XylakiEvangelia Emmanouilidou
September 16, 2020
Preprint
Open Access

The Structure of Human Tyrosine Hydroxylase Reveals the Mechanism for Feedback Inhibition by Dopamine

ResearchSquare
José ValpuestaAurora Martínez
September 20, 2020
Preprint
Open Access

D1, not D2, dopamine receptor activation dramatically improves MPTP-induced parkinsonism unresponsive to levodopa

BioRxiv : the Preprint Server for Biology
Richard Bernard MailmanX. Huang
September 26, 2020
Review
Open Access

A Critical LRRK at the Synapse? The Neurobiological Function and Pathophysiological Dysfunction of LRRK2

Frontiers in Molecular Neuroscience
Naila Kuhlmann, Austen J Milnerwood
September 17, 2020
Review

Pharmacological Treatment of Early Motor Manifestations of Parkinson Disease (PD)

Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics
Michelle Ann C Sy, Hubert H Fernandez

Sign up to follow this feed and discover related papers.

Related Feeds

ALS

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS & FTD: TDP-43

ALS shares with a considerable proportion of FTD cases the same neuropathological substrate, namely, inclusions of abnormally phosphorylated protein tdp-43 (ptdp-43). Here are the latest discoveries pertaining to ptdp-43 and these diseases.

ALS - Pathogenic Mechanisms

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS - Phenotypes

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating phenotypes associated with this genetically heterogeneous disorder.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here are the latest discoveries pertaining to this disease.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS therapies here.

ALS: Transposon de-silencing

Transposon silencing is a form of transcriptional gene silencing. These gene silencing mechanisms are impaired in Amyotrophic lateral sclerosis (ALS). Here are the latest discoveries pertaining to transposon silencing and this disease.

Age-related Dementia

Age-related dementia (Alzheimer's disease) results from the destructive impact of the pulse on cerebral vasculature. Evidence is reviewed that the neuropathology of the dementia is caused by the breakdown of small cerebral vessels (silent microbleeds), that the microbleeds result from pulse-induced damage to the cerebral vessels, and that pulse becomes increasingly destructive with age, because of the age-related stiffening of the aorta and great arteries, which causes an increase in the intensity of the pressure pulse. Discover the latest research on age-related dementia here.

© 2020 Meta ULC. All rights reserved
/feed-previews/lrrk2-inhibitors/283fc400-1ae4-4464-8bfe-28c5d4831403